(ADXS)—ADRO reports preliminary data from pLADD neoantigen program: https://globenewswire.com/news-release/2018/04/26/1488070/0/en/Aduro-Biotech-Presents-Early-Observations-From-its-Personalized-Neoantigen-based-pLADD-Therapy-Clinical-Study-at-European-Neoantigen-Summit.html